Tapentadol is partly metabolized via the hepatic enzymes CYP2C9, CYP2C19, and CYP2D6 so it innately has interactions with medications that greatly enhance or repress the activity/expression of a number of of these enzymes, together with with substrates of those enzymes (because of Competitors with the enzyme); some enzyme mediators/substrates call https://geneh676fcs7.wikiconversation.com/user